Jan Kus
Overview
Explore the profile of Jan Kus including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
370
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Munchhalfen M, Gorg R, Haberl M, Lober J, Willenbrink J, Schwarzt L, et al.
Nat Commun
. 2024 Aug;
15(1):6971.
PMID: 39138218
Ligation of the B cell antigen receptor (BCR) initiates humoral immunity. However, BCR signaling without appropriate co-stimulation commits B cells to death rather than to differentiation into immune effector cells....
2.
Lewandowska K, Baranska I, Sobiecka M, Radwan-Rohrenschef P, Dybowska M, Franczuk M, et al.
Diagnostics (Basel)
. 2022 Nov;
12(11).
PMID: 36428827
Hypersensitivity pneumonitis (HP) is one of the interstitial lung diseases with clearly established diagnostic criteria. Nevertheless, pharmacologic treatment recommendations are still lacking. Most specialists use steroids as first-line drugs, sometimes...
3.
Piotrowski W, Martusewicz-Boros M, Bialas A, Barczyk A, Batko B, Blasinska K, et al.
Adv Respir Med
. 2022 Oct;
90(5):425-450.
PMID: 36285980
The recommendations were developed as answers to previously formulated questions concerning everyday diagnostic and therapeutic challenges. They were developed based on a review of the current literature using the GRADE...
4.
Sobiecka M, Szturmowicz M, Lewandowska K, Kowalik A, Lyzwa E, Zimna K, et al.
BMC Pulm Med
. 2021 Dec;
21(1):416.
PMID: 34920701
Background: Idiopathic pulmonary fibrosis (IPF) and chronic hypersensitivity pneumonitis share commonalities in pathogenesis shifting haemostasis balance towards the procoagulant and antifibrinolytic activity. Several studies have suggested an increased risk of...
5.
Kolonics-Farkas A, Sterclova M, Mogulkoc N, Kus J, Hajkova M, Muller V, et al.
Drug Saf
. 2020 Aug;
43(10):971-980.
PMID: 32734423
Introduction: Nintedanib, a tyrosine kinase receptor inhibitor, may be associated with increased bleeding risk. Thus, patients with an inherited predisposition to bleeding, or those receiving therapeutic doses of anticoagulants or...
6.
Majewski S, Bialas A, Buchczyk M, Gomolka P, Gorska K, Jagielska-Len H, et al.
BMC Pulm Med
. 2020 May;
20(1):122.
PMID: 32366291
Background: Pirfenidone is an antifibrotic agent approved for the treatment of idiopathic pulmonary fibrosis (IPF). The drug is available for Polish patients with IPF since 2017. The PolExPIR study aimed...
7.
Sobiecka M, Lewandowska K, Kober J, Franczuk M, Skoczylas A, Tomkowski W, et al.
Lung
. 2020 Mar;
198(3):547-554.
PMID: 32206858
Introduction: Pulmonary hypertension (PH) is a well-recognised complication of interstitial lung diseases (ILD), which worsens prognosis and impairs exercise capacity. Echocardiography is the most widely used, non-invasive method for PH...
8.
Piotrowski W, Bestry I, Bialas A, Boros P, Grzanka P, Jassem E, et al.
Adv Respir Med
. 2020 Mar;
88(1):41-93.
PMID: 32153010
Introduction: This document presents the guidelines of the Polish Respiratory Society (PTChP, Polskie Towarzystwo Chorób Płuc) for diagnosis and treatment of idiopathic pulmonary fibrosis (IPF), developed by agroup of Polish...
9.
Szturmowicz M, Baranska I, Jedrych M, Bartoszuk I, Radwan-Roehrenschef P, Rozy A, et al.
Adv Respir Med
. 2019 May;
87(2):83-89.
PMID: 31038718
Introduction: Hypersensitivity pneumonitis (HP) is the third most common interstitial lung disease after idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Pathogenesis of HP is related to repeated exposure to inhaled...
10.
Szturmowicz M, Siemion-Szczesniak I, Wyrostkiewicz D, Klatt M, Brzezinska S, Zabost A, et al.
Adv Respir Med
. 2018 Dec;
PMID: 30594992
Introduction: An increasing incidence rate of respiratory isolates of non-tuberculous mycobacteria (NTM) has been noted recently in most European countries as well as in the US. Despite many publications, there...